Today's Portrait Highlights

Gothia Forum

Gothia Forum is a unit within the Västra Götaland region, and works as a meeting point and voluntary resource for everyone working with clinical research in the region. Researchers in the Västra Götaland region, as well as Swedish and foreign research companies can turn to us. We want to strengthen and improve the collaboration between healthcare, academia and industry to strengthen clinical research in the Västra Götaland region. Apart from our own resources, Gothia Forum has a wide network, and works as a point of contact for those looking for research resources or specialist competencies in the Västra Götaland region. We can help with contacts, information and advice. Gothia Forum's aim is to make Västra Götaland the most attractive region for high quality clinical research in Europe.

InnoGate

Innogate supports private and public partners in developing and networking skills and other assets that are important to accelerate entrepreneurship, innovation, value addition and competitiveness. Services include: knowledge services such as market and competitiveness analysis, research and training activities; management services such as project development, project implementation and project result multiplication; and international co-operation services such as cluster-to-cluster collaboration and trade facilitation. Innogate has worked with a number of industries including agro-processing, life-science, IT and cleantech – and in diverse economic contexts.

QPS

Founded in 1995, QPS is a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development. We provide quality services to pharmaceutical and biotechnology clients Worldwide. QPS is well known as a leading CRO for CNS drug development. The availability of the most predictive disease models and unparalleled experience with studies performed for biopharmaceutical companies of all sizes turn QPS into the first choice for most research needs. Validated transgenic and non-transgenic in vitro and in vivo models cover most targets of AD, PD, HD and other neurodegenerative diseases.